Orforglipron 36 mg beats 12 mg on every metabolic outcome measured, with adverse events comparable

Design

systematic review and fixed-effects meta-analysis of six randomised controlled trials, searched to March 2026

Population

3,459 adults with obesity, with and without type 2 diabetes

Primary outcome

percentage and absolute body weight change, with BMI, HbA1c, waist circumference, lipids, blood pressure and adverse events

Effect

36 mg gave greater reductions than 12 mg in body weight, BMI, HbA1c and waist circumference (all p < 0.00001) and in triglycerides and systolic blood pressure (both p = 0.002); adverse events comparable

Six randomised trials, 3,459 adults with obesity with and without type 2 diabetes, pooled in a fixed-effects meta-analysis comparing the two maintenance doses that trial programmes have most often used. The 36 mg dose gave greater reductions in percentage and absolute body weight, BMI, HbA1c and waist circumference, and in triglycerides and systolic blood pressure. Adverse events were comparable between doses, including gastrointestinal events and pancreatic measures.

The interest here is not whether an oral GLP-1 receptor agonist works — that question is already answered — but what a maintenance dose should be once titration is done. A clinician who stops at 12 mg because the patient is tolerating it well is leaving weight and glycaemic benefit on the table, and this analysis says the trade-off usually assumed for that extra benefit did not appear in the pooled safety outcomes.

Two cautions sit inside the paper itself. Small increases in ALT and AST were seen with 36 mg, and the constituent trials were not designed or sized to detect rare or long-term harm. The authors' own conclusion is deliberately conditional: consider the higher maintenance dose where clinically appropriate.

Orforglipron is an investigational oral agent and its licensing position in India is not something this analysis addresses. Check the current regulatory status before counselling a patient who has read about it.

• Where orforglipron is prescribed, treat 36 mg as the maintenance target rather than a dose escalation of last resort
• Check ALT and AST before and during treatment — small rises were seen at the higher dose
• Do not stop titration simply because a patient is comfortable at 12 mg; comfort is not the endpoint
• Confirm the current regulatory status in India before discussing availability with a patient
• Record which dose the weight and HbA1c response was achieved on, so a later prescriber is not guessing

The statistics, in plain English

The abstract reports significance levels — p < 0.00001 for weight, BMI, HbA1c and waist circumference, p = 0.002 for triglycerides and systolic blood pressure — without pooled point estimates, so how much more the higher dose delivers cannot be read off this summary. A very small p-value tells you the difference is unlikely to be chance; it says nothing about whether the difference is large enough to matter to a patient. The pooling used a fixed-effects model, which assumes the trials are estimating one common effect; where trials differ in population or duration that assumption narrows the confidence intervals more than a random-effects model would.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.